Factors Affecting Energy Metabolism and Prognosis in Patients with Amyotrophic Lateral Sclerosis.

1 Desport JC, Preux PM, Truong TC, Vallat JM,

Sautereau D, Couratier P. Nutritional status is

a prognostic factor for survival in ALS patients. Neurology. 1999;53:1059–63.

2 Kasarskis EJ, Berryman S, Vanderleest JG,

Schneider AR, McClain CJ. Nutritional status

of patients with amyotrophic lateral sclerosis:

relation to the proximity of death. Am J Clin

Nutr. 1996;63:130–7.

3 Chio A, Mora G, Leone M, Mazzini L, Cocito

D, Giordana MT, et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology.

2002;59:99–103.

4 Traynor BJ, Codd MB, Corr B, Forde C, Frost

E, Hardiman OM. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: a

population-based study. Arch Neurol. 2000;

57:1171–6.

5 Chio A, Calvo A, Moglia C, Mazzini L, Mora

G. Phenotypic heterogeneity of amyotrophic

lateral sclerosis: a population based study. J

Neurol Neurosurg Psychiatry. 2011; 82: 740–

6.

6 del Aguila MA, Longstreth WT Jr, McGuire

V, Koepsell TD, van Belle G. Prognosis in

amyotrophic lateral sclerosis: a populationbased study. Neurology. 2003;60:813–9.

7 Millul A, Beghi E, Logroscino G, Micheli A,

Vitelli E, Zardi A. Survival of patients with

amyotrophic lateral sclerosis in a populationbased registry. Neuroepidemiology. 2005; 25:

114–9.

Energy Metabolism and Prognosis in ALS

8 Marin B, Desport JC, Kajeu P, Jesus P, Nicolaud B, Nicol M, et al. Alteration of nutritional status at diagnosis is a prognostic factor for

survival of amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry. 2011;

82:628–34.

9 Jawaid A, Murthy SB, Wilson AM, Qureshi

SU, Amro MJ, Wheaton M, et al. A decrease

in body mass index is associated with faster

progression of motor symptoms and shorter

survival in ALS. Amyotroph Lateral Scler.

2010;11:542–8.

10 Dardiotis E, Siokas V, Sokratous M, Tsouris

Z, Aloizou AM, Florou D, et al. Body mass

index and survival from amyotrophic lateral

sclerosis: a meta-analysis. Neurol Clin Pract.

2018;8:437–44.

11 Kimura F, Fujimura C, Ishida S, Nakajima H,

Furutama D, Uehara H, et al. Progression rate

of ALSFRS-R at time of diagnosis predicts

survival time in ALS. Neurology. 2006; 66:

265–7.

12 Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R, Mohammadi B. ALSFRS-R score and

its ratio: a useful predictor for ALS-progression. J Neurol Sci. 2008;275:69–73.

13 Czaplinski A, Yen AA, Appel SH. Forced vital

capacity (FVC) as an indicator of survival and

disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2006;77:

390–2.

14 Schmidt EP, Drachman DB, Wiener CM,

Clawson L, Kimball R, Lechtzin N. Pulmonary predictors of survival in amyotrophic

lateral sclerosis: use in clinical trial design.

Muscle Nerve. 2006;33:127–32.

Ann Nutr Metab

DOI: 10.1159/000518908

15 Genton L, Viatte V, Janssens JP, Héritier AC,

Pichard C. Nutritional state, energy intakes

and energy expenditure of amyotrophic lateral sclerosis (ALS) patients. Clin Nutr. 2011;

30:553–9.

16 Muscaritoli M, Kushta I, Molfino A, Inghilleri

M, Sabatelli M, Rossi Fanelli F. Nutritional

and metabolic support in patients with amyotrophic lateral sclerosis. Nutrition. 2012; 28:

959–66.

17 Desport JC, Torny F, Lacoste M, Preux PM,

Couratier P. Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegener Dis. 2005;2:202–7.

18 Bouteloup C, Desport JC, Clavelou P, Guy N,

Derumeaux-Burel H, Ferrier A, et al. Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol. 2009; 256:

1236–42.

19 Ngo ST, Steyn FJ, McCombe PA. Body mass

index and dietary intervention: implications

for prognosis of amyotrophic lateral sclerosis.

J Neurol Sci. 2014;340:5–12.

20 Georges M, Morélot-Panzini C, Similowski T,

Gonzalez-Bermejo J. Noninvasive ventilation

reduces energy expenditure in amyotrophic

lateral sclerosis. BMC Pulm Med. 2014;14:17.

21 Vaisman N, Lusaus M, Nefussy B, Niv E, Comaneshter D, Hallack R, et al. Do patients

with amyotrophic lateral sclerosis (ALS) have

increased energy needs? J Neurol Sci. 2009;

279:26–9.

22 Ichihara N, Namba K, Ishikawa-Takata K, Sekine K, Takase M, Kamada Y, et al. Energy

requirement assessed by doubly-labeled water method in patients with advanced amyotrophic lateral sclerosis managed by tracheotomy positive pressure ventilation. Amyotroph Lateral Scler. 2012;13:544–9.

23 Harris JA, Benedict FG. A biometric study of

human basal metabolism. Proc Natl Acad Sci

USA. 1918;4:370–3.

24 Shimizu T, Ishikawa-Takata K, Sakata A,

Nagaoka U, Ichihara N, Ishida C, et al. The

measurement and estimation of total energy

expenditure in Japanese patients with ALS: a

doubly labelled water method study. Amyotroph Lateral Scler Frontotemporal Degener.

2017;18:37–45.

25 Wang Z, Heshka S, Gallagher D, Boozer CN,

Kotler DP, Heymsfield SB. Resting energy expenditure-fat-free mass relationship: new insights provided by body composition modeling. Am J Physiol Endocrinol Metab. 2000;

279:E539–45.

26 Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, Hino K, Nishiguchi S. JSH guidelines for

sarcopenia in liver disease (first edition): recommendation from the working group for

creation of sarcopenia assessment criteria in

the JSH. Hepatol Res. 2016;46(10):951.

27 Cedarbaum JM, Stambler N, Malta E, Fuller

C, Hilt D, Thurmond B, et al. The ALSFRS-R:

a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (Phase III). J

Neurol Sci. 1999;169:13–21.

28 Weir JB. New methods for calculating metabolic rate with special reference to protein

metabolism. J Physiol. 1949;109(1–2):1–9.

29 Sasaki M, Johtatsu T, Kurihara M, Iwakawa

H, Tanaka T, Bamba S, et al. Energy expenditure in Japanese patients with severe or moderate ulcerative colitis. J Clin Biochem Nutr.

2010;47:32–6.

30 Takaoka A, Sasaki M, Kurihara M, Iwakawa

H, Inoue M, Bamba S, et al. Comparison of

energy metabolism and nutritional status of

hospitalized patients with Crohn’s disease

and those with ulcerative colitis. J Clin Biochem Nutr. 2015;56:208–14.

31 Shinsyu A, Bamba S, Kurihara M, Matsumoto

H, Sonoda A, Inatomi O, et al. Inflammatory

cytokines, appetite-regulating hormones, and

energy metabolism in patients with gastrointestinal cancer. Oncol Lett. 2020;20:1469–79.

Ann Nutr Metab

DOI: 10.1159/000518908

32 Yasuhara S, Maekawa M, Bamba S, Kurihara

M, Nakanishi N, Yamamoto T, et al. Energy

metabolism and nutritional status in hospitalized patients with chronic heart failure. Ann

Nutr Metab. 2020;76:129–39.

33 Long CL, Schaffel N, Geiger JW, Schiller WR,

Blakemore WS. Metabolic response to injury

and illness: estimation of energy and protein

needs from indirect calorimetry and nitrogen

balance. JPEN J Parenter Enteral Nutr. 1979;

3:452–6.

34 Wills AM, Hubbard J, Macklin EA, Glass J,

Tandan R, Simpson EP, et al. Hypercaloric

enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial.

Lancet. 2014;383:2065–72.

35 Ludolph AC, Dorst J, Dreyhaupt J, Weishaupt

JH, Kassubek J, Weiland U, et al. Effect of

high-caloric nutrition on survival in amyotrophic lateral sclerosis. Ann Neurol. 2020;87:

206–16.

36 Kasarskis EJ, Mendiondo MS, Matthews DE,

Mitsumoto H, Tandan R, Simmons Z, et al.

Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis.

Am J Clin Nutr. 2014;99:792–803.

37 Jesus P, Fayemendy P, Marin B, Nicol M,

Sourisseau H, Boirie Y, et al. Increased resting

energy expenditure compared with predictive

theoretical equations in amyotrophic lateral

sclerosis. Nutrition. 2020;77:110805.

38 Jesus P, Marin B, Fayemendy P, Nicol M, Lautrette G, Sourisseau H, et al. Resting energy

expenditure equations in amyotrophic lateral

sclerosis, creation of an ALS-specific equation. Clin Nutr. 2019;38:1657–65.

39 Miyake R, Tanaka S, Ohkawara K, IshikawaTakata K, Hikihara Y, Taguri E, et al. Validity

of predictive equations for basal metabolic

rate in Japanese adults. J Nutr Sci Vitaminol.

2011;57:224–32.

40 Bone AE, Hepgul N, Kon S, Maddocks M.

Sarcopenia and frailty in chronic respiratory

disease. Chron Respir Dis. 2017;14:85–99.

41 Ooi PH, Hager A, Mazurak VC, Dajani K,

Bhargava R, Gilmour SM, et al. Sarcopenia in

chronic liver disease: impact on outcomes.

Liver Transpl. 2019;25:1422–38.

42 Kobayashi A, Kaido T, Hamaguchi Y, Okumura S, Shirai H, Yao S, et al. Impact of sarcopenic obesity on outcomes in patients undergoing hepatectomy for hepatocellular carcinoma. Ann Surg. 2019;269:924–31.

43 Nishigori T, Obama K, Sakai Y. Assessment of

body composition and impact of sarcopenia

and sarcopenic obesity in patients with gastric

cancer. Transl Gastroenterol Hepatol. 2020;5:

22.

44 Stangl-Kremser J, Mari A, Lai LY, Lee CT,

Vince R, Zaslavsky A, et al. Sarcopenic obesity and its prognostic impact on urologic

cancers: a systematic review. J Urol. 2021:

101097JU0000000000001873.

45 Huisman MH, Seelen M, van Doormaal PT,

de Jong SW, de Vries JH, van der Kooi AJ, et

al. Effect of presymptomatic body mass index

and consumption of fat and alcohol on amyotrophic lateral sclerosis. JAMA Neurol. 2015;

72:1155–62.

46 Hollinger SK, Okosun IS, Mitchell CS. Antecedent disease and amyotrophic lateral sclerosis: what is protecting whom? Front Neurol.

2016;7:47.

47 Delaye JB, Patin F, Piver E, Bruno C, Vasse M,

Vourc’h P, et al. Low IDL-B and high LDL-1

subfraction levels in serum of ALS patients. J

Neurol Sci. 2017;380:124–7.

48 Dedic SI, Stevic Z, Dedic V, Stojanovic VR,

Milicev M, Lavrnic D. Is hyperlipidemia correlated with longer survival in patients with

amyotrophic lateral sclerosis? Neurol Res.

2012;34:576–80.

49 Sutedja NA, van der Schouw YT, Fischer K,

Sizoo EM, Huisman MH, Veldink JH, et al.

Beneficial vascular risk profile is associated

with amyotrophic lateral sclerosis. J Neurol

Neurosurg Psychiatry. 2011;82:638–42.

50 Dorst J, Kühnlein P, Hendrich C, Kassubek J,

Sperfeld AD, Ludolph AC. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic

lateral sclerosis. J Neurol. 2011;258:613–7.

51 Chio A, Calvo A, Bovio G, Canosa A, Bertuzzo D, Galmozzi F, et al. Amyotrophic lateral

sclerosis outcome measures and the role of albumin and creatinine: a population-based

study. JAMA Neurol. 2014;71:1134–42.

52 Huang R, Guo X, Chen X, Zheng Z, Wei Q,

Cao B, et al. The serum lipid profiles of amyotrophic lateral sclerosis patients: a study from

south-west China and a meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:359–65.

53 Wei QQ, Chen Y, Cao B, Ou RW, Zhang L,

Hou Y, et al. Blood hemoglobin A1c levels and

amyotrophic lateral sclerosis survival. Mol

Neurodegener. 2017;12:69.

Kurihara et al.

...